Factors of microinflammation in non-diabetic chronic kidney disease: a pilot study.
Bacterial Translocation
/ immunology
Biomarkers
/ blood
C-Reactive Protein
/ analysis
Female
Gastrointestinal Microbiome
/ immunology
Humans
Indican
/ blood
Indoleacetic Acids
/ blood
Inflammation
/ metabolism
Kidney Function Tests
/ methods
Male
Oxidative Stress
Patient Acuity
Pilot Projects
Renal Dialysis
/ methods
Renal Insufficiency, Chronic
/ blood
Sulfuric Acid Esters
/ blood
Uremia
/ diagnosis
Bacterial translocation
CKD
Microinflammation
Oxidative stress
Uremic toxins
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
21 04 2020
21 04 2020
Historique:
received:
30
12
2019
accepted:
12
04
2020
entrez:
23
4
2020
pubmed:
23
4
2020
medline:
4
9
2021
Statut:
epublish
Résumé
The relationships between digestive bacterial translocation, uremic toxins, oxidative stress and microinflammation in a population of chronic kidney disease (CKD) patients without metabolic nor inflammatory disease are unknown. Bacterial translocation, uremic toxins, oxidative stress, and inflammation were assessed by measuring plasma levels of 16S ribosomal DNA (16S rDNA), p-cresyl sulfate (PCS), indoxyl sulfate (IS), indole acetic acid (IAA), F2-isoprostanes, hsCRP and receptor I of TNFα (RITNFα) in patients without metabolic nor inflammatory disease. 44 patients with CKD from stage IIIB to V and 14 controls with normal kidney function were included from the nephrology outpatients. 11 patients under hemodialysis (HD) were also included. Correlations between each factor and microinflammation markers were studied. 16S rDNA levels were not increased in CKD patients compared to controls but were decreased in HD compared to non-HD stage V patients (4.7 (3.9-5.3) vs 8.6 (5.9-9.7) copies/μl, p = 0.002). IS, PCS and IAA levels increased in HD compared to controls (106.3 (73.3-130.4) vs 3.17 (2.4-5.1) μmol/l, p < 0.0001 for IS; 174.2 (125-227.5) vs 23.7 (13.9-52.6) μmol/l, p = 0.006 for PCS; and 3.7 (2.6-4.6) vs 1.3 (1.0-1.9) μmol/l, p = 0.0002 for IAA). Urea increased in non-HD stage V patients compared to controls (27.6 (22.7-30.9) vs 5.4 (4.8-6.4) mmol/l, p < 0.0001) and was similar in HD and in non-HD stage V (19.3 (14.0-24.0) vs 27.6 (22.7-30.9) mmol/l, p = 0.7). RITNFα levels increased in HD patients compared to controls (12.6 (9.6-13.3) vs 1.1 (1.0-1.4) ng/ml, p < 0.0001); hsCRP levels increased in non-HD stage V patients compared to controls (2.9 (1.4-8.5) vs 0.8 (0.5-1.7) mg/l, p = 0.01) and remained stable in HD patients (2.9 (1.4-8.5) vs 5.1 (0.9-11.5) mg/l, p = 1). F2-isoprostanes did not differ in CKD patients compared to controls. Among uremic toxins, IS and urea were correlated to RITNFα (r = 0.8, p < 0.0001 for both). PCS, IS and urea were higher in patients with hsCRP≧5 mg/l (p = 0.01, 0.04 and 0.001 respectively). 16S rDNA, F2-isoprostanes were not correlated to microinflammation markers in our study. In CKD patients without any associated metabolic nor inflammatory disease, only PCS, IS, and urea were correlated with microinflammation. Bacterial translocation was decreased in patients under HD and was not correlated to microinflammation.
Sections du résumé
BACKGROUND
The relationships between digestive bacterial translocation, uremic toxins, oxidative stress and microinflammation in a population of chronic kidney disease (CKD) patients without metabolic nor inflammatory disease are unknown.
METHODS
Bacterial translocation, uremic toxins, oxidative stress, and inflammation were assessed by measuring plasma levels of 16S ribosomal DNA (16S rDNA), p-cresyl sulfate (PCS), indoxyl sulfate (IS), indole acetic acid (IAA), F2-isoprostanes, hsCRP and receptor I of TNFα (RITNFα) in patients without metabolic nor inflammatory disease. 44 patients with CKD from stage IIIB to V and 14 controls with normal kidney function were included from the nephrology outpatients. 11 patients under hemodialysis (HD) were also included. Correlations between each factor and microinflammation markers were studied.
RESULTS
16S rDNA levels were not increased in CKD patients compared to controls but were decreased in HD compared to non-HD stage V patients (4.7 (3.9-5.3) vs 8.6 (5.9-9.7) copies/μl, p = 0.002). IS, PCS and IAA levels increased in HD compared to controls (106.3 (73.3-130.4) vs 3.17 (2.4-5.1) μmol/l, p < 0.0001 for IS; 174.2 (125-227.5) vs 23.7 (13.9-52.6) μmol/l, p = 0.006 for PCS; and 3.7 (2.6-4.6) vs 1.3 (1.0-1.9) μmol/l, p = 0.0002 for IAA). Urea increased in non-HD stage V patients compared to controls (27.6 (22.7-30.9) vs 5.4 (4.8-6.4) mmol/l, p < 0.0001) and was similar in HD and in non-HD stage V (19.3 (14.0-24.0) vs 27.6 (22.7-30.9) mmol/l, p = 0.7). RITNFα levels increased in HD patients compared to controls (12.6 (9.6-13.3) vs 1.1 (1.0-1.4) ng/ml, p < 0.0001); hsCRP levels increased in non-HD stage V patients compared to controls (2.9 (1.4-8.5) vs 0.8 (0.5-1.7) mg/l, p = 0.01) and remained stable in HD patients (2.9 (1.4-8.5) vs 5.1 (0.9-11.5) mg/l, p = 1). F2-isoprostanes did not differ in CKD patients compared to controls. Among uremic toxins, IS and urea were correlated to RITNFα (r = 0.8, p < 0.0001 for both). PCS, IS and urea were higher in patients with hsCRP≧5 mg/l (p = 0.01, 0.04 and 0.001 respectively). 16S rDNA, F2-isoprostanes were not correlated to microinflammation markers in our study.
CONCLUSIONS
In CKD patients without any associated metabolic nor inflammatory disease, only PCS, IS, and urea were correlated with microinflammation. Bacterial translocation was decreased in patients under HD and was not correlated to microinflammation.
Identifiants
pubmed: 32316931
doi: 10.1186/s12882-020-01803-y
pii: 10.1186/s12882-020-01803-y
pmc: PMC7175551
doi:
Substances chimiques
Biomarkers
0
Indoleacetic Acids
0
Sulfuric Acid Esters
0
indoleacetic acid
6U1S09C61L
C-Reactive Protein
9007-41-4
Indican
N187WK1Y1J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
141Subventions
Organisme : University hospital of Nimes
ID : "Thématiques phares et Thématiques émergentes"
Pays : International
Références
Clin J Am Soc Nephrol. 2011 Jan;6(1):133-41
pubmed: 20876680
Kidney Int. 2016 Mar;89(3):532-4
pubmed: 26880447
Clin Sci (Lond). 2017 Jan 1;131(1):3-12
pubmed: 27872172
J Am Soc Nephrol. 2015 Oct;26(10):2504-11
pubmed: 25733525
AIDS. 2016 Apr 24;30(7):1069-74
pubmed: 27032111
Immunity. 2013 Aug 22;39(2):372-85
pubmed: 23973224
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Sep 1;872(1-2):133-40
pubmed: 18706873
Nephron. 2015;130(2):92-8
pubmed: 25967288
Toxins (Basel). 2014 Mar 04;6(3):934-49
pubmed: 24599232
Kidney Int. 2004 Feb;65(2):442-51
pubmed: 14717914
Kidney Int Suppl. 2002 May;(80):109-14
pubmed: 11982824
PLoS One. 2017 Jan 18;12(1):e0170034
pubmed: 28099495
Am J Nephrol. 2013;37(1):1-6
pubmed: 23258127
Am J Epidemiol. 2008 May 15;167(10):1226-34
pubmed: 18385206
Clin J Am Soc Nephrol. 2019 May 7;14(5):692-701
pubmed: 30962186
Curr Heart Fail Rep. 2017 Aug;14(4):251-265
pubmed: 28667492
Nephrol Ther. 2010 Jul;6(5 Suppl):7-12
pubmed: 20728862
Kidney Int. 1998 Jul;54(1):236-44
pubmed: 9648084
Nat Med. 2016 Jun;22(6):598-605
pubmed: 27158904
Alcohol Clin Exp Res. 2018 Jan;42(1):32-40
pubmed: 29030980
J Clin Endocrinol Metab. 2014 Jul;99(7):2575-83
pubmed: 24735424
J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):149-53
pubmed: 24047967
J Am Soc Nephrol. 2015 Jul;26(7):1732-46
pubmed: 25349205
Pediatr Nephrol. 2011 Jan;26(1):19-28
pubmed: 20526632
Antioxid Redox Signal. 2015 Nov 10;23(14):1144-70
pubmed: 26415143
J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Aug 1;879(23):2281-6
pubmed: 21727042
Crit Care Med. 2001 Jul;29(7):1393-8
pubmed: 11445693
Nephrol Dial Transplant. 2012 Jul;27(7):2686-93
pubmed: 22131233
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Diabetes. 2007 Jul;56(7):1761-72
pubmed: 17456850
J Clin Invest. 2006 Jul;116(7):1793-801
pubmed: 16823477
Oxid Med Cell Longev. 2018 Jan 17;2018:4237812
pubmed: 29576848
Kidney Blood Press Res. 2011;34(1):12-9
pubmed: 21071957
Nat Rev Nephrol. 2012 May 22;8(7):403-12
pubmed: 22614789
Am J Kidney Dis. 2006 Apr;47(4):565-77
pubmed: 16564934
J Pharm Biomed Anal. 2014 Mar;90:161-6
pubmed: 24378611
Inflamm Bowel Dis. 2015 Feb;21(2):297-306
pubmed: 25590952
J Thromb Haemost. 2006 Mar;4(3):566-73
pubmed: 16405517
Semin Dial. 2009 Jul-Aug;22(4):334-9
pubmed: 19708977
Am J Nephrol. 2012;36(5):438-43
pubmed: 23128155
Kidney Int. 2013 Jun;83(6):1029-41
pubmed: 23325084